Skip to content

Stoke Therapeutics, Inc. STOK Other Non Program Costs Research And Development — Operating Expenses

Other product segments

Zorevunersen
-$19.85M-12.3%
Payroll And Other Personnel Costs Research And Development
-$16.12M-46.4%
Payroll And Other Personnel Costs Sales General And Administrative
-$11.06M
Other Non Program Costs Sales General And Administrative
-$5.16M
Other External Program Costs
-$3.18M-73.8%
ADOA
-$1.86M-54.8%
SYNGAP1
-$745K-118%
MECP2
$0+100%

Similar metrics at other companies

Dianthus Therapeutics logo
DNTHOther Costs — Research And Development Expense
$1.49M+25.5%
BioCryst Pharmaceuticals logo
BCRXOther non-program specific and indirect costs — Research and Development Expense (Excluding Acquired in Process Cost)
$7.42M+13.3%
Tyra Biosciences, Inc. logo
TYRAOther Development Programs — Research And Development Expense
$849K+65.2%
Disc Medicine logo
IRONOther Research — Research And Development Expense
$2.17M+18.2%
Amylyx Pharmaceuticals, Inc. logo
AMLXOther Programs — Research And Development Expense Excluding Acquired In Process Cost
$7.98M+111%
Rapport Therapeutics, Inc. logo
RAPPOther Costs — Research And Development Expense
$1.97M+24.7%

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$1.94B+436%
Enterprise value$1.79B+1,855%
P/S60.4×+58.5×

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0.0×
Current ratio+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s other non program costs research and development — operating expenses.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stoke Therapeutics, Inc.'s other non program costs research and development — operating expenses?
Stoke Therapeutics, Inc. (STOK) reported other non program costs research and development — operating expenses of -$1.68M in Q1 2026.
How has Stoke Therapeutics, Inc.'s other non program costs research and development — operating expenses changed year-over-year?
Stoke Therapeutics, Inc.'s other non program costs research and development — operating expenses decreased by 19.4% year-over-year, from -$1.41M to -$1.68M.
What is the long-term trend for Stoke Therapeutics, Inc.'s other non program costs research and development — operating expenses?
Over 2 years (2023 to 2025), Stoke Therapeutics, Inc.'s other non program costs research and development — operating expenses has grown at a 28.1% compound annual growth rate (CAGR), from -$3.74M to -$6.15M.
What does other non program costs research and development — operating expenses mean?
This metric represents the aggregate research and development expenditures that are not directly attributable to specific clinical programs or therapeutic candidates. It captures general overhead, infrastructure costs, and platform-wide research activities necessary to support the broader drug discovery pipeline. Monitoring these costs provides insight into the company's investment in foundational technology and administrative support for its research operations.